Revolution Medicines GAAP EPS of -$1.31 misses by $0.29

2 hours ago 1

Revolution Medicines press release (NASDAQ:RVMD): Q2 GAAP EPS of -$1.31 misses by $0.29.
Cash, cash equivalents and marketable securities were $2.1 billion as of June 30, 2025..
Net loss was $247.8 million for the quarter ended June 30, 2025, compared to net loss

Recommended For You